#USA #Anixa Biosciences #San Jose #CAR-T therapy #Breast Cancer Vaccine

Anixa Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company specializing in the development of innovative cancer therapies, is gearing up to present at the H.C. Wainwright 28th Annual Global Investment Conference. Scheduled for September 14-16, 2026, this event marks a pivotal moment for the company as it showcases significant breakthroughs in ovarian cancer treatment and breast cancer vaccination strategies.

Key Highlights of the Presentation

Dr. Amit Kumar, Chairman and CEO of Anixa, will present critical updates about their ongoing clinical trials that aim to revolutionize cancer care. One of the standout innovations is their lira-cel, a CAR-T therapy targeting ovarian cancer, which has progressed to the fifth dose level in an ongoing Phase 1 trial. This trial is notable for treating patients with recurrent, resistant ovarian cancer who have previously failed conventional therapies.

In this fifth cohort of the trial, the groundbreaking incorporation of lymphodepletion is being evaluated, which previously has not been done at this stage. Remarkably, four participants have surpassed a year of survival following treatment, with one patient reaching an impressive milestone of nearly 28 months.

Breast Cancer Vaccine Development

In addition to its work on ovarian cancer, Anixa will discuss its promising breast cancer vaccine, developed in collaboration with the Cleveland Clinic. This vaccine has recently completed its Phase 1 clinical trial. Impressively, all primary endpoints of the trial have been met, showcasing 74% of participants demonstrating the anticipated immune responses defined by the protocol. The company is now gearing up for a Phase 2 trial, bolstered by funding from the U.S. Department of Defense, and looks forward to building on this early success.

Collaboration with Prestigious Institutions

Anixa’s progress is largely credited to its strategic partnerships with renowned cancer research institutions. Collaborations with the Moffitt Cancer Center and Cleveland Clinic not only enhance their research capabilities but also bring forth cutting-edge therapies that leverage advanced technologies. The distinctive chimeric endocrine receptor-T cell (CER-T) technology utilized in their ovarian cancer treatment is a prime example of how partnership can drive innovation.

Dr. Kumar expresses enthusiasm about the company’s trajectory, stating, "This is an exciting time for Anixa, with our ovarian cancer CAR-T program now dosing at the highest level evaluated in the trial and our breast cancer vaccine advancing toward Phase 2." Such advancements are expected to pave the way for more effective cancer treatments that could significantly improve survival rates and quality of life for patients in need.

Event Details

For those interested in following Anixa’s presentation, it will be available to view online beginning at 7 AM ET on September 11, 2026, and will remain accessible for 90 days thereafter. To view the webcast, please visit H.C. Wainwright Event Link.

Conclusion

As Anixa Biosciences continues to innovate in the field of oncology, its upcoming presentation at the H.C. Wainwright conference represents an important opportunity to highlight significant clinical advancements in cancer therapies. With strong partnerships and a focus on patient outcomes, Anixa aims to not only contribute to cancer treatment but also to redefine standards within the biotechnology landscape. The anticipation for their next steps in clinical trials serves as a beacon of hope in the ongoing fight against cancer.